查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2007889

再生醫學技術市場預測至2034年—按產品類型、原料、技術、應用、最終用戶和地區分類的全球分析

Regenerative Medicine Technologies Market Forecasts to 2034 - Global Analysis By Product Type, Source, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球再生醫學技術市場規模將達到 184 億美元，並在預測期內以 19.8% 的複合年成長率成長，到 2034 年將達到 782 億美元。

再生醫學是指生物醫學的一個交叉學科領域，它致力於利用生物體的修復和自我再生機制來修復、替換或再生受損的組織和器官。這包括幹細胞療法、基因治療載體、組織工程構建體、生物材料支架和基於細胞的免疫療法。這些技術利用自體、同種異體和異種細胞來源，並結合生物製程平台、3D生物列印系統和基於CRISPR的基因編輯工具，以治療整形外科、心臟科、神經科、皮膚科和腫瘤科的疾病。

基因治療的監管核准

基因療法的監管核准正在加速再生醫學市場的擴張。 FDA和EMA對治療遺傳疾病的里程碑式核准，證明了先進細胞和基因療法的商業性和臨床可行性。多種罕見疾病基因療法的核准，樹立了市場價格標桿，並表明了支付意願，從而吸引了大量投資，推動更廣泛的再生醫學技術研發。在核准產品的支持下，產能的擴張進一步降低了單位成本，並使更多患者能夠獲得這項技術。

複雜的製造和規模化挑戰

複雜的生物製造要求和規模化生產挑戰是再生醫學技術商業化面臨的最重大營運障礙之一。自體細胞療法的生產需要為每位患者量身定做個人化的生產過程，難以標準化，導致單次給藥成本高昂，與更廣泛的醫療保健系統的經濟效益不符。雖然異體細胞平台的開發緩解了一些規模化生產的限制，但也引入了免疫抗原性管理的複雜性。細胞增殖、製劑配製和分銷流程中的污染風險和無菌要求，需要投入大量資金以確保符合GMP規範。

整形外科再生醫學的應用

再生醫學在整形外科的應用大規模，因為它比目前的手術和藥物療法更能有效地應對全球老齡化人口中日益普遍的肌肉骨骼疾病。利用生物材料支架和生長因子遞送平台進行軟骨修復、骨再生和肌腱癒合的應用正在順利推進監管核准流程。由於治療成本和報銷條件與現有標準治療方法相當，骨科醫生將再生醫學輔助療法納入既定的商業性流程後，已初見成效。

與定價和還款永續性相關的挑戰

定價和報銷永續性的挑戰對再生醫學技術開發商構成系統性的商業性威脅。這是因為根治性療法需要新的支付模式，而傳統的年度保費或固定費率支付（空洞化）結構無法滿足這些需求。儘管目前正與支付方積極就基於價值的支付框架、年金式報銷方案和基於結果的支付機制進行談判，但尚未建立標準化的實施框架。醫療技術評估機構對再生醫學定價申請的審查極為嚴格，這延長了產品上市時間。

新冠疫情的影響：

新冠疫情擾亂了臨床實驗醫學的臨床試驗計劃，導致試驗中心關閉、病患招募暫停，多個後期計畫因此延期一至兩年。然而，疫情期間對mRNA技術的投資加速了適用於再生醫學基因治療載體的遞送平台的創新。疫情後，監管機構和生產商合作制定了臨床試驗韌性框架，從根本上改善了專案連續性規劃。

在預測期內，支架技術領域預計將佔據最大的市場佔有率。

由於組織工程在整形外科、創傷治療和心臟修復等領域具有廣泛的臨床效用，以及相對成熟的生產製造和監管核准體系，預計支架技術領域將在預測期內佔據最大的市場佔有率。水凝膠、生物陶瓷和可生物分解聚合物等生物相容性支架材料已在多個已通過核准的醫療設備產品中取得了商業性成功。 3D生物列印技術在支架設計中的日益普及，使得支架能夠根據患者的特定解剖結構進行客製化，從而拓展了其臨床應用範圍。

在預測期內，自體細胞細分市場預計將呈現最高的複合年成長率。

在預測期內，自體細胞療法領域預計將呈現最高的成長率，這主要得益於CAR-T細胞療法在骨髓惡性腫瘤治療中市場滲透率的不斷提高、自體軟骨細胞移植術在軟骨修復中的應用日益廣泛以及自體幹細胞移植在造血重建中的應用不斷成長。自體細胞療法的監管核准正在加速推進，多個處於III期臨床試驗階段的項目已取得積極的療效數據。由於對生產自動化的投資，自體細胞療法的生產成本正在逐漸降低。

市佔率最大的地區：

在整個預測期內，北美預計將保持最大的市場佔有率，這得益於其集中的已通過核准的細胞和基因治療產品、一流的學術和醫學研究基礎設施，以及私人和政府對再生醫學技術開發的大量投資。美國食品藥物管理局（FDA）的生技藥品評估和研究中心（CBER）已建立完善的監管流程，以支持細胞和基因療法的商業化。包括百時美施貴寶和吉利德科學主要企業在CAR-T療法市場保持主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率。促成這一成長的因素包括：日本創新性的「先岳」（SAKIGAKE）認定，該認定加速了再生醫學的核准；韓國積極主動的細胞療法法規結構；以及中國對國內幹細胞療法研發項目的巨額投資。亞太地區各國政府對國家再生醫學中心的資助正在建立臨床試驗基礎設施，這為全球技術合作創造了機遇，並加速了該地區產品的上市。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，我們可以提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需要進行可行性測試）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要企業市佔率分析
  • 產品基準評效和效能比較

第5章 全球再生醫學技術市場：依產品類型分類

  • 幹細胞療法
  • 組織工程
  • 基因治療
  • 生物材料
  • 鷹架技術
  • 細胞免疫療法
  • 其他產品類型

第6章：全球再生醫學技術市場：依來源分類

  • 自體細胞
  • 同種異體細胞
  • 外來細胞
  • 胚胎幹細胞
  • 成體幹細胞
  • 誘導性多功能幹細胞
  • 其他來源

第7章 全球再生醫學技術市場：依技術分類

  • 3D生物列印
  • CRISPR基因編輯
  • 細胞再程式化
  • 奈米科技
  • 生物製程技術
  • 生物反應器

第8章 全球再生醫學技術市場：依應用分類

  • 整形外科
  • 循環系統
  • 神經病學
  • 皮膚科
  • 腫瘤學
  • 創傷治療
  • 其他用途

第9章 全球再生醫學技術市場：依最終用戶分類

  • 醫院
  • 專科診所
  • 研究機構
  • 生技公司
  • 製藥公司
  • 學術機構
  • 其他最終用戶

第10章 全球再生醫學技術市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第11章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第12章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第13章：公司簡介

  • Astellas Pharma Inc.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Johnson & Johnson
  • Vericel Corporation
  • Mesoblast Limited
  • Organogenesis Holdings Inc.
  • Bluebird Bio, Inc.
  • Sangamo Therapeutics
  • CRISPR Therapeutics AG
  • Editas Medicine
  • Intellia Therapeutics
  • Takeda Pharmaceutical Company Limited
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Amgen Inc.
Product Code: SMRC34767

According to Stratistics MRC, the Global Regenerative Medicine Technologies Market is accounted for $18.4 billion in 2026 and is expected to reach $78.2 billion by 2034 growing at a CAGR of 19.8% during the forecast period. Regenerative medicine technologies refer to a multidisciplinary field of biomedical science focused on restoring, replacing, or regenerating damaged tissues and organs through harnessing biological mechanisms of repair and self-renewal. They encompass stem cell therapies, gene therapy vectors, tissue engineering constructs, biomaterial scaffolds, and cell-based immunotherapies. These technologies utilize autologous, allogeneic, and xenogeneic cellular sources combined with bioprocessing platforms, 3D bioprinting systems, and CRISPR-based gene editing tools to address orthopedic, cardiac, neurological, dermatological, and oncological indications.

Market Dynamics:

Driver:

Gene Therapy Regulatory Approvals

Gene therapy regulatory approvals are accelerating regenerative medicine market expansion as landmark FDA and EMA clearances for hereditary disease treatments validate the commercial and clinical viability of advanced cellular and genetic therapies. Approval of multiple gene therapies for rare disorders has established market pricing precedents and demonstrated willingness-to-pay dynamics that are attracting substantial investment into broader regenerative technology pipelines. Manufacturing capability scaling supported by approved products is additionally reducing per-unit costs and improving technology accessibility for wider patient populations.

Restraint:

Complex Manufacturing and Scaling Challenges

Complex biomanufacturing requirements and scaling challenges represent the most significant operational barrier facing regenerative medicine technology commercialization. Autologous cell therapy manufacturing requires individualized patient-specific production runs that are difficult to standardize, creating high per-dose costs incompatible with broad healthcare system economics. Allogeneic platform development mitigates some scaling constraints but introduces immunogenicity management complexity. Contamination risks and sterility maintenance requirements across cell expansion, formulation, and distribution workflows impose substantial GMP compliance investment.

Opportunity:

Orthopedic Regeneration Applications

Orthopedic regeneration applications represent a high-volume commercial opportunity as aging global populations experience rising musculoskeletal disorder prevalence that regenerative interventions can address more effectively than current surgical and pharmaceutical options. Cartilage repair, bone regeneration, and tendon healing applications using biomaterial scaffolds and growth factor delivery platforms are progressing through regulatory pathways. Orthopedic surgeon adoption of regenerative adjuncts within established surgical workflows is generating early commercial traction with attractive procedure economics and reimbursement comparability to existing standard interventions.

Threat:

Pricing and Reimbursement Sustainability Challenges

Pricing and reimbursement sustainability challenges pose a systemic commercial threat to regenerative medicine technology developers, as single-administration curative therapies with transformative clinical outcomes require novel payment models that traditional annual insurance premium and capitation structures cannot accommodate. Value-based payment frameworks, annuity-style reimbursement schemes, and outcomes-linked payment mechanisms are under active negotiation with payers but lack standardized implementation frameworks. Health technology assessment bodies are applying exceptional scrutiny to regenerative therapy pricing submissions, extending market access timelines.

Covid-19 Impact:

COVID-19 disrupted regenerative medicine clinical trial timelines through site closures and patient enrollment suspensions, delaying several late-stage programs by one to two years. However, pandemic mRNA technology investments accelerated delivery platform innovations applicable to regenerative gene therapy vectors. Post-pandemic regulatory agencies and manufacturers collaborated on clinical trial resilience frameworks that have structurally improved program continuity planning.

The scaffold technologies segment is expected to be the largest during the forecast period

The scaffold technologies segment is expected to account for the largest market share during the forecast period, due to broad clinical utility across tissue engineering applications in orthopedics, wound healing, and cardiac repair, combined with relatively well-established manufacturing and regulatory approval infrastructure. Biocompatible scaffold materials including hydrogels, bioceramics, and biodegradable polymers have achieved commercial traction in multiple approved medical device products. Growing 3D bioprinting integration with scaffold design is enabling patient-specific anatomical geometry customization, expanding clinical application scope.

The autologous cells segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the autologous cells segment is predicted to witness the highest growth rate, driven by escalating CAR-T cell therapy commercial penetration across hematological malignancies, expanding autologous chondrocyte implantation for cartilage repair, and growing autologous stem cell transplantation for hematopoietic reconstitution. Regulatory approval momentum for autologous cell-based therapies is compounding, with multiple programs in Phase III generating positive efficacy data. Manufacturing automation investments are progressively reducing autologous cell therapy production costs.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to concentration of approved cell and gene therapy products, leading academic medical research infrastructure, and substantial private and government investment in regenerative medicine technology development. The U.S. FDA's Center for Biologics Evaluation and Research has established robust regulatory pathways supporting cell and gene therapy commercialization. Key companies including Bristol-Myers Squibb Company and Gilead Sciences, Inc. maintain leading commercial CAR-T therapy market positions.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to Japan's innovative SAKIGAKE designation providing expedited regenerative medicine approvals, South Korea's active cell therapy regulatory framework, and China's massive investment in domestic stem cell therapy development programs. Government funding for national regenerative medicine centers across Asia Pacific is creating clinical trial infrastructure that is attracting global technology partnership opportunities and accelerating regional commercial launches.

Key players in the market

Some of the key players in Regenerative Medicine Technologies Market include Astellas Pharma Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Johnson & Johnson, Vericel Corporation, Mesoblast Limited, Organogenesis Holdings Inc., Bluebird Bio, Inc., Sangamo Therapeutics, CRISPR Therapeutics AG, Editas Medicine, Intellia Therapeutics, Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences, Inc., and Amgen Inc..

Key Developments:

In March 2026, Organogenesis Holdings Inc. received CMS reimbursement expansion for its regenerative wound care biomaterial platform across additional chronic wound indication categories.

In February 2026, Mesoblast Limited secured regulatory approval in Australia for its allogeneic mesenchymal stem cell therapy targeting treatment-refractory pediatric graft-versus-host disease.

In January 2026, CRISPR Therapeutics AG initiated pivotal trial enrollment for its next-generation gene-edited autologous T-cell therapy targeting aggressive relapsed/refractory B-cell malignancies.

In November 2025, Intellia Therapeutics reported transformative Phase II gene editing therapy data demonstrating durable disease modification in patients with hereditary transthyretin amyloidosis.

Product Types Covered:

  • Stem Cell Therapy
  • Tissue Engineering
  • Gene Therapy
  • Biomaterials
  • Scaffold Technologies
  • Cell-based Immunotherapy
  • Other Product Types

Sources Covered:

  • Autologous Cells
  • Allogeneic Cells
  • Xenogeneic Cells
  • Embryonic Stem Cells
  • Adult Stem Cells
  • Induced Pluripotent Stem Cells
  • Other Sources

Technologies Covered:

  • 3D Bioprinting
  • CRISPR Gene Editing
  • Cell Reprogramming
  • Nanotechnology
  • Bioprocessing Technologies
  • Bioreactors

Applications Covered:

  • Orthopedics
  • Cardiology
  • Neurology
  • Dermatology
  • Oncology
  • Wound Healing
  • Other Applications

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Research Institutes
  • Biotechnology Companies
  • Pharmaceutical Companies
  • Academic Institutes
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 3032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Regenerative Medicine Technologies Market, By Product Type

  • 5.1 Stem Cell Therapy
  • 5.2 Tissue Engineering
  • 5.3 Gene Therapy
  • 5.4 Biomaterials
  • 5.5 Scaffold Technologies
  • 5.6 Cell-based Immunotherapy
  • 5.7 Other Product Types

6 Global Regenerative Medicine Technologies Market, By Source

  • 6.1 Autologous Cells
  • 6.2 Allogeneic Cells
  • 6.3 Xenogeneic Cells
  • 6.4 Embryonic Stem Cells
  • 6.5 Adult Stem Cells
  • 6.6 Induced Pluripotent Stem Cells
  • 6.7 Other Sources

7 Global Regenerative Medicine Technologies Market, By Technology

  • 7.1 3D Bioprinting
  • 7.2 CRISPR Gene Editing
  • 7.3 Cell Reprogramming
  • 7.4 Nanotechnology
  • 7.5 Bioprocessing Technologies
  • 7.6 Bioreactors

8 Global Regenerative Medicine Technologies Market, By Application

  • 8.1 Orthopedics
  • 8.2 Cardiology
  • 8.3 Neurology
  • 8.4 Dermatology
  • 8.5 Oncology
  • 8.6 Wound Healing
  • 8.7 Other Applications

9 Global Regenerative Medicine Technologies Market, By End User

  • 9.1 Hospitals
  • 9.2 Specialty Clinics
  • 9.3 Research Institutes
  • 9.4 Biotechnology Companies
  • 9.5 Pharmaceutical Companies
  • 9.6 Academic Institutes
  • 9.7 Other End Users

10 Global Regenerative Medicine Technologies Market, By Geography

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 United Kingdom
    • 10.2.2 Germany
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Netherlands
    • 10.2.7 Belgium
    • 10.2.8 Sweden
    • 10.2.9 Switzerland
    • 10.2.10 Poland
    • 10.2.11 Rest of Europe
  • 10.3 Asia Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 South Korea
    • 10.3.5 Australia
    • 10.3.6 Indonesia
    • 10.3.7 Thailand
    • 10.3.8 Malaysia
    • 10.3.9 Singapore
    • 10.3.10 Vietnam
    • 10.3.11 Rest of Asia Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Colombia
    • 10.4.4 Chile
    • 10.4.5 Peru
    • 10.4.6 Rest of South America
  • 10.5 Rest of the World (RoW)
    • 10.5.1 Middle East
      • 10.5.1.1 Saudi Arabia
      • 10.5.1.2 United Arab Emirates
      • 10.5.1.3 Qatar
      • 10.5.1.4 Israel
      • 10.5.1.5 Rest of Middle East
    • 10.5.2 Africa
      • 10.5.2.1 South Africa
      • 10.5.2.2 Egypt
      • 10.5.2.3 Morocco
      • 10.5.2.4 Rest of Africa

11 Strategic Market Intelligence

  • 11.1 Industry Value Network and Supply Chain Assessment
  • 11.2 White-Space and Opportunity Mapping
  • 11.3 Product Evolution and Market Life Cycle Analysis
  • 11.4 Channel, Distributor, and Go-to-Market Assessment

12 Industry Developments and Strategic Initiatives

  • 12.1 Mergers and Acquisitions
  • 12.2 Partnerships, Alliances, and Joint Ventures
  • 12.3 New Product Launches and Certifications
  • 12.4 Capacity Expansion and Investments
  • 12.5 Other Strategic Initiatives

13 Company Profiles

  • 13.1 Astellas Pharma Inc.
  • 13.2 Novartis AG
  • 13.3 Pfizer Inc.
  • 13.4 Roche Holding AG
  • 13.5 Johnson & Johnson
  • 13.6 Vericel Corporation
  • 13.7 Mesoblast Limited
  • 13.8 Organogenesis Holdings Inc.
  • 13.9 Bluebird Bio, Inc.
  • 13.10 Sangamo Therapeutics
  • 13.11 CRISPR Therapeutics AG
  • 13.12 Editas Medicine
  • 13.13 Intellia Therapeutics
  • 13.14 Takeda Pharmaceutical Company Limited
  • 13.15 Bristol-Myers Squibb Company
  • 13.16 AbbVie Inc.
  • 13.17 Gilead Sciences, Inc.
  • 13.18 Amgen Inc.

List of Tables

  • Table 1 Global Regenerative Medicine Technologies Market Outlook, By Region (2023-2034)($MN)
  • Table 2 Global Regenerative Medicine Technologies Market Outlook, By Product Type (2023-2034)($MN)
  • Table 3 Global Regenerative Medicine Technologies Market Outlook, By Stem Cell Therapy (2023-2034)($MN)
  • Table 4 Global Regenerative Medicine Technologies Market Outlook, By Tissue Engineering (2023-2034)($MN)
  • Table 5 Global Regenerative Medicine Technologies Market Outlook, By Gene Therapy (2023-2034)($MN)
  • Table 6 Global Regenerative Medicine Technologies Market Outlook, By Biomaterials (2023-2034)($MN)
  • Table 7 Global Regenerative Medicine Technologies Market Outlook, By Scaffold Technologies (2023-2034)($MN)
  • Table 8 Global Regenerative Medicine Technologies Market Outlook, By Cell-based Immunotherapy (2023-2034)($MN)
  • Table 9 Global Regenerative Medicine Technologies Market Outlook, By Other Product Types (2023-2034)($MN)
  • Table 10 Global Regenerative Medicine Technologies Market Outlook, By Source (2023-2034)($MN)
  • Table 11 Global Regenerative Medicine Technologies Market Outlook, By Autologous Cells (2023-2034)($MN)
  • Table 12 Global Regenerative Medicine Technologies Market Outlook, By Allogeneic Cells (2023-2034)($MN)
  • Table 13 Global Regenerative Medicine Technologies Market Outlook, By Xenogeneic Cells (2023-2034)($MN)
  • Table 14 Global Regenerative Medicine Technologies Market Outlook, By Embryonic Stem Cells (2023-2034)($MN)
  • Table 15 Global Regenerative Medicine Technologies Market Outlook, By Adult Stem Cells (2023-2034)($MN)
  • Table 16 Global Regenerative Medicine Technologies Market Outlook, By Induced Pluripotent Stem Cells (2023-2034)($MN)
  • Table 17 Global Regenerative Medicine Technologies Market Outlook, By Other Sources (2023-2034)($MN)
  • Table 18 Global Regenerative Medicine Technologies Market Outlook, By Technology (2023-2034)($MN)
  • Table 19 Global Regenerative Medicine Technologies Market Outlook, By 3D Bioprinting (2023-2034)($MN)
  • Table 20 Global Regenerative Medicine Technologies Market Outlook, By CRISPR Gene Editing (2023-2034)($MN)
  • Table 21 Global Regenerative Medicine Technologies Market Outlook, By Cell Reprogramming (2023-2034)($MN)
  • Table 22 Global Regenerative Medicine Technologies Market Outlook, By Nanotechnology (2023-2034)($MN)
  • Table 23 Global Regenerative Medicine Technologies Market Outlook, By Bioprocessing Technologies (2023-2034)($MN)
  • Table 24 Global Regenerative Medicine Technologies Market Outlook, By Bioreactors (2023-2034)($MN)
  • Table 25 Global Regenerative Medicine Technologies Market Outlook, By Application (2023-2034)($MN)
  • Table 26 Global Regenerative Medicine Technologies Market Outlook, By Orthopedics (2023-2034)($MN)
  • Table 27 Global Regenerative Medicine Technologies Market Outlook, By Cardiology (2023-2034)($MN)
  • Table 28 Global Regenerative Medicine Technologies Market Outlook, By Neurology (2023-2034)($MN)
  • Table 29 Global Regenerative Medicine Technologies Market Outlook, By Dermatology (2023-2034)($MN)
  • Table 30 Global Regenerative Medicine Technologies Market Outlook, By Oncology (2023-2034)($MN)
  • Table 31 Global Regenerative Medicine Technologies Market Outlook, By Wound Healing (2023-2034)($MN)
  • Table 32 Global Regenerative Medicine Technologies Market Outlook, By Other Applications (2023-2034)($MN)
  • Table 33 Global Regenerative Medicine Technologies Market Outlook, By End User (2023-2034)($MN)
  • Table 34 Global Regenerative Medicine Technologies Market Outlook, By Hospitals (2023-2034)($MN)
  • Table 35 Global Regenerative Medicine Technologies Market Outlook, By Specialty Clinics (2023-2034)($MN)
  • Table 36 Global Regenerative Medicine Technologies Market Outlook, By Research Institutes (2023-2034)($MN)
  • Table 37 Global Regenerative Medicine Technologies Market Outlook, By Biotechnology Companies (2023-2034)($MN)
  • Table 38 Global Regenerative Medicine Technologies Market Outlook, By Pharmaceutical Companies (2023-2034)($MN)
  • Table 39 Global Regenerative Medicine Technologies Market Outlook, By Academic Institutes (2023-2034)($MN)
  • Table 40 Global Regenerative Medicine Technologies Market Outlook, By Other End Users (2023-2034)($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.